Success takes the right partner and strong systems.
ATN's Franchise Lens shares the keys to preparing for franchise success.
New research shows GLP-1 users are shelling out roughly $449 a month on fitness amid broader lifestyle shifts, although the general consensus is conflicted on whether weight-loss drugs are a net benefit for the fitness and wellness industry
The focus of the partnership has shifted to whether solutions targeting the microbiome can deliver benefits alongside GLP-1-based medicines
Nestle believes the drugs are also creating a new market for products designed to address the side effects of rapid weight loss
Speaking with top certification organizations and personal training tech providers, ATN surveys how personal training is evolving at the midpoint of 2026
The peptide market keeps growing amid mounting tensions between longevity practitioners and scientists. For some, reward — financial or medical — might outweigh risk
Gyms are evolving to keep up with climbing GLP-1 adoption, offering muscle-preservation workouts, telehealth partnerships and integrated wellness services
The retired NFL legend appeared on Fox Business to tout his partnership with GLP-1-prescribing telehealth platform eMed, Brady's latest move into the wellness space
More than 25% of GLP-1 users in the U.K. reported increasing fitness spending after starting treatment. Those results are promising, but other data shows it's far from a given that weight-loss drugs will prove to be a net benefit for the industry
While U.S. consumers are exposed to constant messaging about peptides, a new report reveals many are still confused about what the therapies are.
Industry leaders pointed to fitness' ability to drive stronger healthcare and social wellness outcomes as key levers for the industry's future. The rise of GLP-1s offers another opportunity, they said.
Sign Up to Our Newsletter
